Hypertension, obesity, and inflammation: The complex designs of a deadly trio

Metabolic Syndrome and Related Disorders

Volumn 8, Issue 4, 2010, Pages 287-294

  Rizvi, Ali A ^a  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; C REACTIVE PROTEIN; ENDOTHELIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HUMAN; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ADAPTIVE IMMUNITY; ANGIOTENSIN II; ATHEROSCLEROSIS; GENES, RAS; HUMANS; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; OXIDATIVE STRESS;

EID: 77955570096     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2009.0116     Document Type: Review

References (103)

1. Meyer G, Merval R, Tedgui A. Effects of pressure-induced wall stretching and convection on low density lipoprotein and albumin uptake in the rabbit aorta. Circ Res 1996;79:532-540.
2. Landmesser U, Hornig B, Drexler H. Endothelial function: A critical determinant in atherosclerosis? Circulation 2004;109:1127-1133.
3. Wang H, Nawata J, Kakudo N, Sugimura K, Suzuki J, Sakuma M, Ikeda J, Shirato K. The upregulation of ICAM-1 and P-selectin requires high blood pressure but not circulating renin-angio- tensin system in vivo. J Hypertens 2004;22:1323-1332.
4. Lemarie CA, Esposito B, Tedgui A, Lehoux S. Pressure-induced vascular activation of nuclear factor-kappaB: role in cell survival. Circ Res 2003;93:207-212.
5. Libby P. Inflammation in atherosclerosis. Nature 2002;420: 868-874.
6. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004;109:112-1110.
7. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: A critical review of the evidence. J Am Med Assoc 2003;290:932-940.
8. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Howe GDO, Pepys MB, Gudnason V. C-Reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397.
9. Schunkert H, Samani NJ. Elevated C-reactive protein in atherosclerosis-chicken or egg? N Engl J Med 2008;359:1953-1955.
10. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008;359:1897-1908.
11. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 2009;302:37-48.
12. Bautista LE, Lopez-Jaramillo P, Vera LM, Casas JP, Otero AP, Guaracao AI. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001;19:857-861.
13. Dauphinot V, Roche F, Kossovsky MP, Schott AM, Pichot V, Gaspoz JM, Gosse P, Barthelmy J-C. C-reactive protein implications in new-onset hypertension in a healthy population initially aged 65 years: The Proof study. J Hypertens 2009;27:736-743.
14. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GD, Day INM, Ebrahim S. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005;25:1051-1056.
15. Schillaci G, Pirro M, Gemelli F, Pasqualini L, Vaudo G, Marchesi S, Siepi D, Bagaglia F, Mannarino E. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens 2003;21:1841-1846.
16. Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003;112:1785-1788.
17. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112:1796-1808.
18. Verma S, Yeh ET. C-reactive protein and atherothrombosis- beyond a biomarker: An actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol 2003;285:R1253-R1256.
19. Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, Li R-K, Mickle DAG, Verma S. C-reactive protein upregu- lates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003;107:1783-1790.
20. Ridker PM, Buring JE, Cook NR, Rifai N. C-Reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: An 8-year follow-up of 14719 initially healthy American women. Circulation 2003;107:391-397.
21. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004;140:167-174.
22. Pedrinelli R, Dell'Omo G, Di Bello V, Pellegrini G, Pucci L, Del Prato S, Penno G. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol 2004;24:2414-2419.
23. Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension 2008;51:8-14.
24. Lim H, Lip G. Interleukin-15 in hypertension: Further insights into inflammation and vascular disease. Am J Hypertension 2005;18:1017-1018.
25. Bravo PE, Morse SS, Borne DM, Erwin A, Aguilar EA, Reisin Leptin and hypertension in obesity. Vasc Health Risk Manag 2006;2:163-169.
26. Virdis A, Schiffrin EL. Vascular inflammation: A role in vascular disease in hypertension? Curr Opin Nephrol Hypertens 2003;12:181-187.
27. Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, LindgarFalk D.E. Long-term effects of inflammation-sensitive plasma proteins and systolic blood pressure on incidence of stroke. Stroke 2002;33:2744-2749.
28. Niskanen L, Laaksonen DE, Nyyssonen K, Punnonen K, Valkonen V-P, Fuentes R, Tuomainen T-P, Salonen R, Salonen JT. Inflammation, abdominal obesity, and smoking as predictors of hypertension. Hypertension 2004;44:859-865.
29. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003;290:2945-2951.
30. Stumpf C, John S, Jukic J, Yilmaz A, Raaz D, Schmieder RE, Danial WG, Garlichs CD. Enhanced levels of platelet P-selectin and circulating cytokines in young patients with mild arterial hypertension. J Hypertens 2005;23:995-1000.
31. Chrysohoou C, Pitsavos C, Panagiotakos DB, Skoumas J, Stefanadis C. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: The ATTICA Study. Am J Hypertens 2004;17:568-573.
32. Yan JC, Ma GS, Wu ZG, Kong XT, Zong RQ, Zhan LZ. Increased levels of CD40-CD40 ligand system in patients with essential hypertension. Clin Chim Acta 2005;355:191-196.
33. Mallat Z, Gojova A, Brun V, Esposito B, Fournier N, Cottrez Tedgui A, Groux H. Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apoli- poprotein E-knockout mice. Circulation 2003;108:1232-1237.
34. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: Risk marker or mediator in atherothrombosis? Hypertension 2004;44:6-11.
35. Mbanya J-CN, Thomas TH, Wilkinson R, Alberti KGMM, Taylor R. Hypertension and hyperinsulinemia: A relation in diabetes but not essential hypertension. Lancet 1988;1:733-734.
36. Manicardi V, Camellini L, Bellodi G, Coscelli C, Ferrannini E. Evidence for an association of high blood pressure and hyperinsulinemia in obese men. J Clin Endocrinol Metab 1986;62:1302-1304.
37. Saad MF, Rewers M, Selby J, Howard G, Jinagouda S, Fahmi S, Zaccaro D, Bergman RN, Savage PJ, Haffner SM. Insulin resistance and hypertension. The Insulin Resistance Atherosclerosis Study. Hypertension 2004;43:1324-1331.
38. Reaven GM. Insulin resistance/compensatory hyperinsuline- mia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003;88:2399-2403.
39. Mikhail N. The metabolic syndrome: insulin resistance. Curr Hypertens Rep 2009;11:156-158.
40. Wheatcroft SB, Williams IL, Shah AM, Kearney MT. Pathophysiological implications of insulin resistance on vascular endothelial function. Diabet Med 2003;20:255-268.
41. Hwu C-M, Liou TL, Hsiao LC, Lin MW. Prehypertension is associated with insulin resistance. QJM 2009 102:705-711.
42. Srinivasan SR, Myers L, Berenson GS. Changes in metabolic syndrome variables since childhood in prehypertensive and hypertensive subjects: The Bogalusa Heart Study. Hypertension 2006;48:33-39.
43. Muller DC, Elahi D, Pratley RE, Tobin JD, Andres R. An epide- miological test of the hyperinsulinemia-hypertension hypothesis. J Clin Endocrinol Metab 1993;76:544-548.
44. Grundy SM. Inflammation, hypertension, and the metabolic syndrome. JAMA 2003;290:3000-3002.
45. Vaziri ND. Causal link between oxidative stress, inflammation, and hypertension. Iran J Kidney Dis 2008;2:1-10.
46. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleu- kin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-{kappa}B transcription factors. Circ Res 1999;84:695-703.
47. Li J, Doerffel Y, Hocher B, Unger T. Inflammation in the genesis of hypertension and its complications-the role of angiotensin II. Nephrol Dial Transplant 2007;22:3107-3109.
48. Capers Q IV, Alexander RW, Lou P, De Leon H, Wilcox JN, Ishizaka N, Howard AB, Taylor WR. Monocyte chemoattrac- tant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 1997;30:1397-1402.
49. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996;97:1916-1923.
50. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148.
51. Andersen K, Pedersen BK. The role of inflammation in vascular insulin resistance with focus on IL-6. Horm Metab Res 2008;40:635-639.
52. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 2005;11:RA194-RA205.
53. Luvara G, Pueyo ME, Philippe M, Mandet C, Savoie F, Henrion D, Michel J-B. Chronic blockade of NO synthase activity induces a proinflammatory phenotype in the arterial wall: Prevention by angiotensin II antagonism. Arterioscler Thromb Vasc Biol 1998;18:1408-1416.
54. LaMarca BB, Bennett WA, Alexander BT, Cockrell K, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: Role of tumor necrosis factor-a. Hypertension 2005;46:1022-1025.
55. Alexander BT, Massey MB, Cockrell KL, Bennett WA, Granger JP. Elevations in plasma TNF in pregnant rats decreases renal nNOS and iNOS and results in hypertension. Am J Hypertens 2002;15:170-175.
56. Dernellis J, Panaretou M. Aortic stiffness is an independent predictor of progression to hypertension in nonhypertensive subjects. Hypertension 2005;45:426-431.
57. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND. Early and sustained inhibition of nuclear factor- kappa B prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther 2005;315:51-57.
58. Manrique C, Lastra G, Gardner M, Sowers JR. The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am 2009;93:569-582.
59. Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, Brown NJ. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 2006;48:1050-1057.
60. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008;51:161-167.
61. Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med 1998;188:661-670.
62. Li J, Culman J, Hortnagl H, Zhao Y, Gerova N, Timm M, Blume Zimmermann M, Seidel K, Dirnagl U, Unger T. Angiotensin AT2 receptor protects against cerebral ischemia-induced neu- ronal injury. FASEB J 2005;19:617-619.
63. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-472.
64. Unger T. Significance of angiotensin type 1 receptor blockade: Why are angiotensin II receptor blockers different? Am J Cardiol 1999;84:9S-15S.
65. Yamada H, Fabris B, Allen AM, Jackson B, Johnston CI, Mendelsohn AO. Localization of angiotensin converting enzyme in rat heart. Circ Res 1991;68:141-149.
66. Potter DD, Sobey CG, Tompkins PK, Rossen JD, Heistad DD. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation 1998; 98:800-807.
67. Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, Kuziel WA, Pagano PJ, Carretero OA. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension 2008;52:256-263.
68. Sandhofer A, Tatarczyk T, Kirchmair R, Iglseder B, Paulweber Patsch JR, Schratzberger P. Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study. Atherosclerosis 2009;206:265-269.
69. Zhao Q, Ishibashi M, Hiasa K, Tan C, Takeshita A, Egashira K. Essential role of vascular endothelial growth factor in angio- tensin II-induced vascular inflammation and remodeling. Hypertension 2004;44:264-270.
70. Baumgartner I, Isner JM. Somatic gene therapy in the cardiovascular system. Annu Rev Physiol 2001;63:427-450.
71. Hermann DM, Zechariah A.Implications of vascular endothelial growth factor for postischemic neurovascular remodeling. J Cereb Blood Flow Metab 2009;29:1620-1643.
72. Wada H, Satoh N, Kitaoka S, Ono K, Morimoto T, Kawamura T, Nakan T, Fujita M, Kita T, Shimatzu A, Hasegawa K. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance. Atherosclerosis 2009;208:512-517.
73. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl JMed 2000;342:145-153.
74. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. The Lancet 2002;359:995-1003.
75. Schieffer B, Wirger A, Meybrunn M, Seitz S, Holtz J, Riede UN, Drexler H. Comparative effects of chronic angiotensin-con- verting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994;89:2273-2282.
76. Sironi L, Gelosa P, Guerrini U, Banfi C, Crippa V, Brioschi M, Gianazza E, Nobili E, Gianella A, de Gasparo M, Tremoli E. Anti-Inflammatory effects of AT1 receptor blockade provide end-organ protection in stroke-prone rats independently from blood pressure fall. J Pharmacol Exp Ther 2004;311:989-995.
77. Schieffer B, Bunte C, Witte J, Hoeper K, Boger RH, Schwedheim E, Drexler H. Comparative effects of ATI-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 2004;44:362-368.
78. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-{gamma} activity. Circulation 2004;109:2054-2057.
79. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, Akishita M, de Gasparo M, Horiuchi M. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with Valsartan in the improvement of inflammation-induced vascular injury Circulation 2001;104:2716-2721.
80. Verma S, Lonn EM, Nanji A, Browne K, Ward R, Robertson A, Conradson H, Hildebrand K, Brant R, Anderson TJ. Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: The ramipril C-reactive protein randomized evaluation (4R) trial results. Can J Cardiol 2009;25:e236-e240.
81. Del Fiorentino A, Cianchetti S, Celi A, Dell'Omo G, Pedrinelli R. The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man. Vasc Health Risk Manag 2009;5:233-242.
82. Ferrario C. Effect of angiotensin receptor blockade on endothelial function: Focus on olmesartan medoxomil. Vasc Health Risk Manag 2009;5:301-314.
83. Ishii H, Tsukada T, Yoshida M. Angiotensin II type-I receptor blocker, candesartan, improves brachial-ankle pulse wave velocity independent of its blood pressure lowering effects in type 2 diabetes patients. Intern Med 2008;47:2013-2018.
84. Negro R. Endothelial effects of antihypertensive treatment: Focus on irbesartan. Vasc Health Risk Manag 2008;4:89-101.
85. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med ClinNAm 2009;93:621-635.
86. Grossman E. Does increased oxidative stress cause hypertension? Diabetes Care 2008;31(Suppl 2):S185-S189.
87. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008;31(Suppl 2):S170-S180.
88. Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol 2007;2:550-562.
89. Manning RD Jr, Tian N, Meng S. Oxidative stress and antioxi- dant treatment in hypertension and the associated renal damage. Am J Nephrol 2005;25:311-317.
90. Guzik TJ, Harrison DG. Endothelial NF-kappaB as a mediator of kidney damage: The missing link between systemic vascular and renal disease? Circ Res 2007;101:227-229.
91. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life Sci 2009;84:705-712.
92. Friederich M, Hansell P, Palm F. Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr Diabetes Rev 2009;5:120-144.
93. Rozman B, Gasperlin M. Stability of vitamins C and E in topical microemulsions for combined antioxidant therapy. Drug Deliv 2007;14:235-245.
94. Iannitti T, Palmieri B. Antioxidant therapy effectiveness: An up to date. Eur Rev Med Pharmacol Sci 2009;13:245-278.
95. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91:281-291.
96. Tedgui A, MallatZ. Hypertension: A novel regulator of adaptive immunity in atherosclerosis? Hypertension 2004;44:257-258.
97. Mazzolai L, Duchosal M, Korber M, Bouzourene K, Aubert J, Hao H, Vallet V, Brunner HR, Nussberger J, Gabbiani G, Hayoz D. Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in apoE-/- mice. Hypertension 2004;44:277-282.
98. Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, Fujita T. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003;42:31-38.
99. Daugherty A, Rateri DL. T lymphocytes in atherosclerosis: The yin-yang of Th1 and Th2 influence on lesion formation. Circ Res 2002;90:1039-1040.
100. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, Soubrier F, Exposito B, Duez H, Fievet C, Staels B, Duverger N, Scherman D, Tedgui A. Protective role of interleu- kin-10 in atherosclerosis. Circ Res 1999;85:el7-e24.
101. Guzik TJ, Mangalat D, Korbut R. Adipocytokines-novel link between inflammation and vascular function? J Physiol Pharmacol 2006;57:505-528.
102. Mathieu P, Poirier P, Pibarot P, Lemieux I, Despres JP. Visceral obesity: The link among inflammation, hypertension, and cardiovascular disease. Hypertension 2009;53:577-584.
103. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med 1989;149:1514-1520.